Background Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with
high morbidity and mortality. Effective treatments for IPF are limited. Several recent studies …

… Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing interstitial lung
disease … The objective of this study was to identify all pharmacologic treatments evaluated for …

Background There are substantial advances in diagnosis and treatment for idiopathic
pulmonary fibrosis (IPF), but without much evidence available on recent mortality and survival …

Summary Background Most data on outcomes in Idiopathic Pulmonary Fibrosis (IPF) pre-dates
current guidelines. Data on rates of infection is sparse; the effect of low-dose …

Background Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor prognosis.
Our objective is to assess the comparative effectiveness of 22 approved or studied IPF …

BACKGROUND: The antifibrotics pirfenidone and nintedanib are both approved for the
treatment of idiopathic pulmonary fibrosis (IPF) by regulatory agencies and are recommended by …

… meta-analysis were conducted in accordance with PRISMA guidelines for systematic reviews
and meta-analyses … : (idiopathic pulmonary fibrosis or pulmonary fibrosis or cryptogenic …

… in the present meta-analysis, which indicated a positive correlation between DM and IPF (OR
1.65, 95% CI 1.30–2.10; P < 0.0001). Meta-regression and subgroup analysis negated the …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. In the last
decades pirfenidone an anti-inflammatory and anti-fibrotic agent has shown benefit in inhibit …

… Idiopathic pulmonary fibrosis is the most common type of idiopathic interstitial pneumonia,
and its incidence and prevalence indicate that it is a disease which heavily impacts healthcare …